+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bronchial Spasms Treatment Market by Treatment Type, Route of Administration, End User - Global Forecast 2025-2030- Product Image
Bronchial Spasms Treatment Market by Treatment Type, Route of Administration, End User - Global Forecast 2025-2030- Product Image
Sale

Bronchial Spasms Treatment Market by Treatment Type, Route of Administration, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6011461
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bronchial Spasms Treatment Market grew from USD 296.81 million in 2023 to USD 309.72 million in 2024. It is expected to continue growing at a CAGR of 4.38%, reaching USD 400.77 million by 2030.

The scope of the bronchial spasms treatment market encompasses various therapies, including bronchodilators, anti-inflammatory medications, and newer biologic agents, aimed at alleviating symptoms of bronchial spasms, a condition characterized by the narrowing of the airways often associated with asthma and chronic obstructive pulmonary disease (COPD). Necessity for treatments arises due to increasing global prevalence of respiratory disorders and patient demand for quicker, more effective relief from acute asthma attacks. Applications are primarily within healthcare settings, such as hospitals and clinics, with growing emphasis on homecare products driven by telemedicine and wearable health technologies that enable remote disease management. End-use is dominated by patients with chronic respiratory conditions and healthcare professionals specializing in pulmonology. Key growth factors include advancements in inhalation drug delivery systems, increasing investment in biologics, and a rising awareness about asthma management. Moreover, opportunities lie in the development of personalized medicine approaches and integration of AI for predictive analysis in disease management. Limitations include high costs associated with biologic therapies, regulatory challenges, and potential side effects of long-term medication use. On the other side, challenges such as disparity in healthcare access and the requirement for robust clinical trials to validate treatment efficacy persist. Innovation and research areas ripe for exploration include next-generation inhalers, non-invasive diagnostics, and the exploration of plant-based medicines. As for the nature of the market, it is highly competitive, with both pharmaceutical giants and niche biopharma firms vying for market share. Market dynamics are influenced by regulatory policies, patent cliffs, and shifting consumer preferences towards holistic care models. To leverage these opportunities, stakeholders must focus on strategic partnerships, investing in R&D, and navigating regulatory pathways that expedite product launch without compromising safety or efficacy.

Understanding Market Dynamics in the Bronchial Spasms Treatment Market

The Bronchial Spasms Treatment Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising prevalence of asthma and COPD globally
    • Increasing government spending and healthcare initiatives
    • Growing awareness regarding bronchial spasms and their impact on health
  • Market Restraints
    • High costs associated with treatment and stringent regulations regarding the release of drugs
  • Market Opportunities
    • Strategic partnerships between pharma companies and research institutions
    • Innovations in inhaler devices, nebulizers, and bronchial spasm treatment
  • Market Challenges
    • Adverse effects associated with bronchial spasms treatments

Exploring Porter’s Five Forces for the Bronchial Spasms Treatment Market

Porter’s Five Forces framework further strengthens the insights of the Bronchial Spasms Treatment Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Bronchial Spasms Treatment Market

External macro-environmental factors deeply influence the performance of the Bronchial Spasms Treatment Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Bronchial Spasms Treatment Market

The Bronchial Spasms Treatment Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Bronchial Spasms Treatment Market

The Bronchial Spasms Treatment Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Bronchial Spasms Treatment Market

The Bronchial Spasms Treatment Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchial Spasms Treatment Market, highlighting leading vendors and their innovative profiles. These include Amphastar Pharmaceuticals, Inc, Bayer AG, C.H. Boehringer Sohn AG & Co. KG, CHIESI Farmaceutici S.p.A., Cipla Limited, GlaxoSmithKline plc, Grifols, S.A., Lybrate, Inc., Merck KGaA, Novartis AG, Orion Corporation, Pfizer Inc, Temple University Health System, Inc., Teva Pharmaceutical Industries Ltd, Vectura Group Ltd by Philip Morris International Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Bronchial Spasms Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Treatment Type
    • Medications
      • Bronchodilators
      • Corticosteroids
      • Leukotriene Modifiers
      • Mast Cell Stabilizers
      • Methylxanthines
    • Non-Pharmacological Treatments
      • Oxygen Therapy
      • Pulmonary Rehabilitation
  • Route of Administration
    • Inhalation
    • Intravenous
    • Oral
    • Subcutaneous
  • End User
    • Ambulatory Surgical Centers
    • Homecare Settings
    • Hospitals & Clinics
    • Research & Academic Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of asthma and COPD globally
5.1.1.2. Increasing government spending and healthcare initiatives
5.1.1.3. Growing awareness regarding bronchial spasms and their impact on health
5.1.2. Restraints
5.1.2.1. High costs associated with treatment and stringent regulations regarding the release of drugs
5.1.3. Opportunities
5.1.3.1. Strategic partnerships between pharma companies and research institutions
5.1.3.2. Innovations in inhaler devices, nebulizers, and bronchial spasm treatment
5.1.4. Challenges
5.1.4.1. Adverse effects associated with bronchial spasms treatments
5.2. Market Segmentation Analysis
5.2.1. Treatment Type: Rising usage of medications for immediate relief and long-term management to improve patient quality of life
5.2.2. End User: Consumer preference for homecare settings due to convenience and ease of maintenance
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Bronchial Spasms Treatment Market, by Treatment Type
6.1. Introduction
6.2. Medications
6.2.1. Bronchodilators
6.2.2. Corticosteroids
6.2.3. Leukotriene Modifiers
6.2.4. Mast Cell Stabilizers
6.2.5. Methylxanthines
6.3. Non-Pharmacological Treatments
6.3.1. Oxygen Therapy
6.3.2. Pulmonary Rehabilitation
7. Bronchial Spasms Treatment Market, by Route of Administration
7.1. Introduction
7.2. Inhalation
7.3. Intravenous
7.4. Oral
7.5. Subcutaneous
8. Bronchial Spasms Treatment Market, by End User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Homecare Settings
8.4. Hospitals & Clinics
8.5. Research & Academic Institutes
9. Americas Bronchial Spasms Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Bronchial Spasms Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Bronchial Spasms Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Verona Pharma ohtuvayre gains FDA approval as first novel inhaled COPD treatment
12.3.2. Viatris and Kindeva launch FDA-approved generic Symbicort, Breyna, to enhance asthma and COPD treatment accessibility
12.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. BRONCHIAL SPASMS TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. BRONCHIAL SPASMS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. BRONCHIAL SPASMS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. BRONCHIAL SPASMS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BRONCHIAL SPASMS TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MAST CELL STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PULMONARY REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 46. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 47. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 48. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 51. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 52. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 53. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 74. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 75. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 79. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 80. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 89. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 90. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 118. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 119. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 120. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 133. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 135. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 136. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 140. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 141. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 144. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 145. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 146. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 151. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 154. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 155. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 156. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 165. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 166. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 180. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 181. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 185. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 186. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 189. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 190. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 191. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 210. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 211. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 225. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 226. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. BRONCHIAL SPASMS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 239. BRONCHIAL SPASMS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Bronchial Spasms Treatment market, which are profiled in this report, include:
  • Amphastar Pharmaceuticals, Inc
  • Bayer AG
  • C.H. Boehringer Sohn AG & Co. KG
  • CHIESI Farmaceutici S.p.A.
  • Cipla Limited
  • GlaxoSmithKline plc
  • Grifols, S.A.
  • Lybrate, Inc.
  • Merck KGaA
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc
  • Temple University Health System, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Vectura Group Ltd by Philip Morris International Inc.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 309.72 Million
Forecasted Market Value ( USD ) by 2030 $ 400.77 Million
Compound Annual Growth Rate4.3%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Bronchial Spasms - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Bronchial Spasms - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Bronchial Dysplasia - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Bronchial Dysplasia - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Bronchial Hyperreactivity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Bronchial Hyperreactivity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 131 Pages
  • Global
From
Eprazinone Market by Indication, Product, Distribution Channel, Mode of Administation - Global Forecast 2025-2030 - Product Image

Eprazinone Market by Indication, Product, Distribution Channel, Mode of Administation - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Non-Cystic Fibrosis Bronchiectasis Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F - Product Image

Non-Cystic Fibrosis Bronchiectasis Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From

About the Bronchial Spasm Drug Market

The Bronchial Spasm Drug market is a subset of the larger Respiratory Drugs market. Bronchial Spasm Drugs are used to treat bronchospasm, a condition in which the airways of the lungs become constricted, making it difficult to breathe. These drugs are typically administered through inhalation, and can be used to treat both acute and chronic bronchospasm. Commonly prescribed Bronchial Spasm Drugs include short-acting beta-agonists, long-acting beta-agonists, anticholinergics, and theophylline. The Bronchial Spasm Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Merck & Co., Boehringer Ingelheim, Novartis, Sanofi, Pfizer, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.